Publication: Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment
Program
KU-Authors
KU Authors
Co-Authors
Ibis, Kamuran
Saglam, Sezer
Saglam, Esra Kaytan
Yilmazbayhan, Dilek
Toker, Alper
Ozkan, Berker
Hancer, Veysel S.
Buyukdogan, Murat
Disci, Rian
Pilanci, Kezban Nur
Advisor
Publication Date
2018
Language
English
Type
Journal Article
Journal Title
Journal ISSN
Volume Title
Abstract
Background: To assess the prognostic importance of carbonic anhydrase IX (CA IX), a hypoxic biomarker, after neoadjuvant treatment in Stage III non-small cell lung cancer (NSCLC) patients. Methods: Tissue CA IX expression was examined after surgical resection in 77 patients who had undergone neoadjuvant treatment. The effects of CA IX overexpression and other clinical factors on disease-free survival and overall survival were investigated. Results: In multivariate analysis, number of neoadjuvant chemotherapy (CT) courses and gender emerged as significant independent predictors for disease-free survival, where administration of 2-3 courses of neoadjuvant chemotherapy (CT) (HR, 3.2 [95% CI 1.3-7.6], p = 0.009) and female gender were associated with poor survival (HR, 3.2 [95% CI 1.3-7.7], p = 0.009). The only significant independent predictor for overall survival was recurrence (HR, 5.6 [95% CI 2.4-12.8], p < 0.001). On the other hand, CA IX overexpression was not associated with disease free survival (p = 0.560) or overall survival (p = 0.799). Discussion: Our results do not suggest a prognostic role for CA IX overexpression in stage III NSCLC patients who received neoadjuvant treatment.
Description
Source:
Pathology Research and Practice
Publisher:
Elsevier
Keywords:
Subject
Pathology